Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 66 member A (FAM66A), also known as FAM86B2-DT, is a long non-coding RNA (lncRNA) implicated in cancer biology, particularly in the regulation of tumor metastasis in lung adenocarcinoma and the prognosis of small cell lung cancer[1]. It may participate in cell signaling pathways, notably interacting with vitamin D receptor signaling, and is under investigation for its potential role as a diagnostic or prognostic biomarker in various cancers. FAM66A is not a receptor, enzyme, or conventional druggable therapeutic target, but rather is studied for its regulatory and biomarker roles in disease[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 66 member A (FAM66A).